Epigenetic therapy of cancer: past, present and future
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer HISTONE DEACETYLASE INHIBITORS: UNDERSTANDING A NEW WAVE OF ANTICANCER AGENTS Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells Histone deacetylase as a new target for cancer chemotherapy Histone deacetylase inhibitors: Multifunctional anticancer agents Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B It’s About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells